Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) and Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by company insiders. Comparatively, 13.0% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Monopar Therapeutics and Mersana Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monopar Therapeutics | N/A | N/A | -$15.59 million | ($3.33) | -25.44 |
| Mersana Therapeutics | $40.50 million | 0.98 | -$69.19 million | ($14.62) | -0.54 |
Monopar Therapeutics has higher earnings, but lower revenue than Mersana Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Monopar Therapeutics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Monopar Therapeutics and Mersana Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monopar Therapeutics | 0 | 1 | 8 | 1 | 3.00 |
| Mersana Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
Monopar Therapeutics currently has a consensus price target of $86.22, indicating a potential upside of 1.76%. Mersana Therapeutics has a consensus price target of $56.60, indicating a potential upside of 612.85%. Given Mersana Therapeutics’ higher probable upside, analysts plainly believe Mersana Therapeutics is more favorable than Monopar Therapeutics.
Profitability
This table compares Monopar Therapeutics and Mersana Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monopar Therapeutics | N/A | -41.76% | -39.49% |
| Mersana Therapeutics | -212.94% | N/A | -54.85% |
Summary
Monopar Therapeutics beats Mersana Therapeutics on 8 of the 13 factors compared between the two stocks.
About Monopar Therapeutics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
About Mersana Therapeutics
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
